blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2424990

EP2424990 - COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  20.05.2016
Database last updated on 02.07.2024
Most recent event   Tooltip20.05.2016Refusal of applicationpublished on 22.06.2016  [2016/25]
Applicant(s)For all designated states
The Johns Hopkins University
3400 North Charles Street
Baltimore, MD 21218 / US
[2012/10]
Inventor(s)01 / WU, Tzyy-Choou
11002 Nacirema Lane
Stevenson MD 21153 / US
02 / HUNG, Chien-Fu
13 Ballyhean Court
Timonium MD 21093 / US
 [2012/10]
Representative(s)Lock, Graham James, et al
Fry Heath & Spence LLP
Unit A, Faraday Court
Faraday Road
Crawley, West Sussex RH10 9PU / GB
[N/P]
Former [2012/10]Lock, Graham James, et al
Fry Heath & Spence LLP The Gables
Massetts Road
Horley, Surrey RH6 7DQ / GB
Application number, filing date10772568.128.04.2010
WO2010US32779
Priority number, dateUS20090173413P28.04.2009         Original published format: US 173413 P
[2012/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010129339
Date:11.11.2010
Language:EN
[2010/45]
Type: A2 Application without search report 
No.:EP2424990
Date:07.03.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 11.11.2010 takes the place of the publication of the European patent application.
[2012/10]
Search report(s)International search report - published on:KR03.03.2011
(Supplementary) European search report - dispatched on:EP15.04.2013
ClassificationIPC:A61K39/00, A61K39/12, A61P35/00, C12N15/12, C12N15/63, C12N15/85
[2013/20]
CPC:
A61K39/0011 (EP,US); A61K39/4611 (EP); A61K39/4644 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/04 (EP);
A61P43/00 (EP); A61K2039/5256 (EP,US); A61K2039/53 (EP,US);
A61K2039/545 (EP,US); A61K2039/57 (EP,US); A61K35/13 (EP,US);
C12N2710/16043 (EP,US); C12N2710/20022 (EP,US); C12N2710/24143 (EP,US) (-)
Former IPC [2012/10]C12N15/63, C12N15/85, C12N15/12, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/10]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERSTÄRKUNG ANTIGENSPEZIFISCHER IMMUNREAKTIONEN[2012/10]
English:COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES[2012/10]
French:COMPOSITIONS ET PROCÉDÉS POUR AMÉLIORER DES RÉPONSES IMMUNITAIRES SPÉCIFIQUES D'ANTIGÈNE[2012/10]
Entry into regional phase24.11.2011National basic fee paid 
24.11.2011Search fee paid 
24.11.2011Designation fee(s) paid 
24.11.2011Examination fee paid 
Examination procedure24.11.2011Examination requested  [2012/10]
06.11.2013Amendment by applicant (claims and/or description)
29.11.2013Despatch of a communication from the examining division (Time limit: M04)
28.03.2014Reply to a communication from the examining division
14.04.2014Despatch of a communication from the examining division (Time limit: M06)
24.10.2014Reply to a communication from the examining division
01.12.2015Application refused, date of legal effect [2016/25]
01.12.2015Date of oral proceedings
05.02.2016Despatch of communication that the application is refused, reason: substantive examination [2016/25]
05.02.2016Minutes of oral proceedings despatched
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.11.2013
Fees paidRenewal fee
25.04.2012Renewal fee patent year 03
29.04.2013Renewal fee patent year 04
28.04.2014Renewal fee patent year 05
27.04.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2006120474  (OXXON THERAPEUTICS LTD [GB], et al) [I] 1-15* examples 1-11 *;
 [XI]WO2007071997  (GLAXO GROUP LTD [GB], et al) [X] 1-5,7,9-13,15 * examples 7,8 * [I] 6,8,14;
 [I]WO2009007336  (GENIMMUNE N V [BE], et al) [I] 1-15 * examples 1-4 *;
 [XI]  - ROSA MARIA DIAZ ET AL, "Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 67, no. 6, doi:10.1158/0008-5472.CAN-06-3974, ISSN 0008-5472, (20070101), pages 2840 - 2848, (20070315), XP008154520 [X] 1-4,6-15 * figures 5,6 * [I] 5

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-06-3974
International search[A]US2004106128  (MAJUMDAR ANISH SEN [US], et al);
 [X]  - CHEN, C-H. ET AL., "Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.", VACCINE, (2000), vol. 18, doi:doi:10.1016/S0264-410X(99)00528-9, pages 2015 - 2022, XP004202497

DOI:   http://dx.doi.org/10.1016/S0264-410X(99)00528-9
 [X]  - KIM, T. W. ET AL., "DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.", HUM. GENE THER., (2005), vol. 16, no. 1, pages 26 - 34
 [XP]  - CHUANG, C-M. ET AL., "Combination of viral oncology and tumor-specific immunity to control established tumors.", CLIN. CANCER RES., (20090715), vol. 15, no. 14, doi:doi:10.1158/1078-0432.CCR-08-2685, pages 4581 - 4588, XP055055082

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-08-2685
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.